Data mining analysis of the prognostic impact of N6-methyladenosine regulators in patients with endometrial adenocarcinoma

We reanalyzed the expression of 16 acknowledged N6-methyladenosine (m6A) RNA regulators in 406 endometrial adenocarcinoma patients and 19 controls using The Cancer Genome Atlas (TCGA) dataset, and further verified our results using Gene Expression Omnibus (GEO) dataset and real-time quantitative polymerase chain reaction. Thirteen m6A RNA methylation regulators were differentially expressed between patients with endometrial adenocarcinoma and controls. FTO, RBM15, and YTHDF1, were identified as independent prognostic markers and closely associated with International Federation of Gynecology and Obstetrics grade in endometrial cancer patients. GEO dataset also verified the differential expression of FTO and RBM15 between patients with endometrial adenocarcinoma and hyperplasia. Functional enrichment and ingenuity pathway analysis network suggested that FTO and RBM15 contributed to the survival of patients with endometrial adenocarcinoma via the regulation of connective tissue development, catabolic process, RNA stability, oxidative demethylation, temperature homeostasis, and energy metabolism through IGF1, IRS1, RBM24, LARP1, and CBFA2T3. The decreased FTO expression and increased RBM15 expression in endometrial adenocarcinoma from our validation cohort was consistent with in silico analysis using TCGA and GEO datasets. In conclusion, m6A methylation regulators, especially FTO, RBM15, and YTHDF1, are critical in the progression and prognosis of endometrial adenocarcinoma.

• Publication year

  2021

• Venue

  Journal of Cancer

• Publication date

  2021-06-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.7150/jca.50868PMID 34149936PMCID 8210566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma

  2020cited by this paper
• m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma.

  2020cited by this paper
• TNFα signalling predicts poor prognosis of patients with endometrial cancer.

  2020cited by this paper
• Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity

  2020cited by this paper
• Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups

  2020cited by this paper
• LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration

  2020cited by this paper
• FTO Demethylates Cyclin D1 mRNA and Controls Cell-Cycle Progression.

  2020cited by this paper
• Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance.

  2020cited by this paper
• Deciphering N6-Methyladenosine-Related Genes Signature to Predict Survival in Lung Adenocarcinoma

  2020cited by this paper
• Emerging role of m6A RNA methylation in nutritional physiology and metabolism

  2020cited by this paper
• Patient perceptions and understanding of obesity related endometrial cancer

  2020cited by this paper
• The role of m6A RNA methylation in cancer.

  2019cited by this paper
• Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma.

  2019cited by this paper
• Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.

  2019cited by this paper
• Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal.

  2018cited by this paper
• Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists

  2018cited by this paper
• m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer

  2018influential reference
• Recognition of RNA N6-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation

  2018cited by this paper
• The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention.

  2017cited by this paper
• The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway

  2017cited by this paper
• The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells

  2017cited by this paper
• Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.

  2017cited by this paper
• YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4–NOT deadenylase complex

  2016cited by this paper
• Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing.

  2016cited by this paper
• Gene expression and pathway analysis of CTNNB1 in cancer and stem cells

  2016influential reference
• FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.

  2015cited by this paper
• HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events.

  2015cited by this paper
• N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.

  2015cited by this paper
• Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5

  2014cited by this paper
• ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility.

  2013cited by this paper
• American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine.

  2012cited by this paper
• Impaired Thermogenesis and Adipose Tissue Development in Mice with Fat-Specific Disruption of Insulin and IGF-1 Signalling

  2012cited by this paper
• N6-Methyladenosine in Nuclear RNA is a Major Substrate of the Obesity-Associated FTO

  2011cited by this paper
• Application of DNA methylation biomarkers for endometrial cancer management

  2008cited by this paper
• Variation in FTO contributes to childhood obesity and severe adult obesity

  2007cited by this paper
• Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells

  2004cited by this paper
• Impact of aging on DNA methylation.

  2003cited by this paper
• Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial

  2001cited by this paper
• Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.

  2000cited by this paper

• The Relationship Between FTO and Female Reproduction System Diseases: Focusing on PCOS, Endometriosis and Cancer and Targeted Therapy Strategy

  2025cites this paper
• RBM15 aggravates endometrial cancer progression by inducing PBK m6A modification to inhibit the p53 pathway

  2025cites this paper
• RBM15 in diseases: Molecular mechanisms and clinical opportunities from RNA m6A methylation

  2025cites this paper
• The emerging function of N6-methyladenosine and its regulators in endometrial cancer; Current knowledge and prospect

  2023cites this paper
• RNA m6A methylation regulators in endometrial cancer (Review)

  2022cites this paper
• Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer

  2022cites this paper
• Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting

  2022cites this paper
• Insight into the structure, physiological function, and role in cancer of m6A readers—YTH domain-containing proteins

  2022cites this paper
• Role of m6A modification in female infertility and reproductive system diseases

  2022cites this paper
• Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer

  2022cites this paper